Expect to see some reviews for Conneqt Pulse to start appearing.
This will tell us if, after years of development, if we have a device worth getting excited about.
This review is very positive - and bodes well ( full review below )
The CONNEQT Pulse is more than just a blood pressure monitor—it’s a comprehensive cardiovascular health tool. With dual BP measurement, arterial biomarkers, and an AI-driven health app, it provides a complete picture of heart health. For individuals who want more than just numbers and need guidance in understanding their results, the CONNEQT App is an invaluable companion.
Final Verdict: ⭐⭐⭐⭐⭐ (5/5) – Highly recommended for proactive heart health management.Selling 8,000 units at A$400 each is not pocket change - $3.2M
But this number will drop back once the pipeline is filled, perhaps weekly sales of 200 units ( $80K a week - $4.2M annual ).
This will be bolstered by some clinical trial wins. Depending on the size of the clinical trial, anywhere between 500 - 10,000 units.
BUT ... the real game begins when CDX achieves OTC clearance from the FDA.
And this sort of review, with ease of use and application, would suggest it is a very real possibility.
Even one major pharmacy ranging the CONNEQT Pulse would be a game changer.
Walgreens operates 8,000 stores in the USA. Of these, about 2,500 are "super stores".
Let's say with OTC, CONNEQT Pulse gets ranged in these 2,500 stores.
Pipeline Sales ( ie, stock the shelf and Walgreens warehouse ) - 5 units per store - A$250 wholesale - $2.5M sales
Then, UPSPW ( units per store per week ) - 3
3 units x 2500 stores x $250 ( wholesale ) = $1.9M per week ~ $100M per year.
And that is why I really like this review - OTC seems very achievable - I believe from the last quarterly testing/research is completed and submission is close. I look forward to a review on progress in this quarterly.
